Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Northera in POTS and Vasovagal Syncope
NCT02558972Phase 2Terminated
- Sponsor
- New York Medical College
- Start
- Sep 2015
- Primary completion
- Dec 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of droxidopa in postural orthostatic tachycardia syndrome (POTS) and vasovagal syncope, sponsored by New York Medical College. Primary endpoints: Splanchnic and lower extremity pooling at 2 weeks, Quality of Life measured by RAND-36 at 6 weeks and 1 more. Started Sep 2015; status: terminated.
02
Drugs
droxidopa
03
Conditions
postural orthostatic tachycardia syndrome (POTS)vasovagal syncope
Beyond the preview
Go deeper on NCT02558972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02558972.